Benitec Biopharma Inc.
BNTC · Pharmaceutical Preparations · 34.4M shares · +62%/yr ↑ shares · EDGAR filings ↗
Reference price $13.44 · est. market cap ~$462M — last insider purchase, 2025-12-29 (estimated from the dated SEC Form 4 price × shares outstanding — not a live quote)
Grade
D46Clinical/early-stage biotech — gene-therapy clinical, extremely cash-rich.
Strengths
- Liquidity — current ratio 54.7 (99.8th)
Risks
- Pre-revenue, deep losses — per metrics
- Pre-revenue/clinical-stage — history of losses & need for capital per risk factors
- Binary clinical & funding risk — per 10-K
Notable findings
- RestatementSee Note 3, Restatement of Prior Period Financial Statements, in the notes to the consolidated financial statements in this Annual Report on Form 10-K, for additional information related to the restat 8-K ↗
- Exec changeRecent 8-K item 5.02 8-K ↗
- Cash burnNegative free cash flow (-23.6M)
- Fund exitedNotable fund(s) exited this quarter: VANGUARD GROUP INC
- Notable holderHeld by 4 notable fund(s): STATE STREET CORP, GOLDMAN SACHS GROUP INC, CITADEL ADVISORS LLC +1 more (as of 2026-03-31)
Quarterly revenue
Last 4 quarters · from SEC filings.
Key metrics
Return on equity
-39.0%
Return on assets
-38.1%
Current ratio
54.7×
Free cash flow
-$24M
EBITDA
-$42M
Tangible book value
$97M
Cash & investments
$98M
Cash runway
17q
Insider transactions · last 18 months
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2025-12-29 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 66K | $13.44 |
| 2025-12-29 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 12K | $13.44 |
| 2025-12-26 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 14K | $13.10 |
| 2025-12-26 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 2.5K | $13.10 |
| 2025-12-23 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 43K | $12.85 |
| 2025-12-23 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 7.4K | $12.85 |
| 2025-12-22 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 2.9K | $12.08 |
| 2025-12-22 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 17K | $12.08 |
| 2025-12-19 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 14K | $11.48 |
| 2025-12-19 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 2.4K | $11.48 |
| 2025-12-18 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 8.7K | $11.24 |
| 2025-12-18 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 1.5K | $11.24 |
| 2025-11-07 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 730K | $13.50 |
| 2025-11-07 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 751K | $13.50 |
| 2025-03-31 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 670 | $13.22 |
| 2025-03-31 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 1.3K | $12.63 |
| 2025-03-31 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 5.1K | $13.22 |
| 2025-03-31 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 9.5K | $12.63 |
| 2025-03-26 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 106K | $13.00 |
| 2025-03-26 | SUVRETTA CAPITAL MANAGEMENT, LLC | Buy | 794K | $13.00 |
| 2025-03-12 | BUCHI J KEVIN | Gift | 104K | — |
| 2025-03-12 | BUCHI J KEVIN | Gift | 104K | — |
| 2025-02-27 | BUCHI J KEVIN | Option exercise | 52K | $3.86 |
All non-derivative Form 4 activity (SEC), newest first.
Clinical trials
| Trial | Title | Phase | Status | Primary completion |
|---|---|---|---|---|
| NCT06185673 ↗ | A Study to Evaluate the Safety and Clinical Activity of Intramuscular Doses of BB-301 Administered to Subjects With Oculopharyngeal Muscular Dystrophy With Dysphagia Oculopharyngeal Muscular Dystrophy | PHASE1/PHASE2 | Recruiting | 2030-11-01 |
| NCT03433027 ↗ | A Study of BB-401 in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Head and Neck Squamous Cell Carcinoma | PHASE2 | Completed | 2018-12-12 |
Source: ClinicalTrials.gov (U.S. NIH) · active studies first.
Notable events (8-K)
| Date | Items | |
|---|---|---|
| 2026-05-29 | Exec/director change | filing ↗ |
| 2026-05-14 | ResultsExhibits | filing ↗ |
| 2026-02-12 | ResultsExhibits | filing ↗ |
| 2025-12-02 | Shareholder vote | filing ↗ |
| 2025-11-14 | ResultsExhibits | filing ↗ |
| 2025-11-07 | Material agreementOtherExhibits | filing ↗ |
| 2025-11-03 | Exec/director changeReg FDOtherExhibits | filing ↗ |
| 2025-09-22 | ResultsExhibits | filing ↗ |
Recent filings
| Form | Filed | Period | Accession |
|---|---|---|---|
| 8-K | 2026-05-29 | 2026-05-22 | 0001193125-26-248289 ↗ |
| 8-K | 2026-05-14 | 2026-05-14 | 0001193125-26-222879 ↗ |
| 10-Q | 2026-05-14 | 2026-03-31 | 0001193125-26-222885 ↗ |
| 10-K/A | 2026-03-20 | 2025-06-30 | 0001193125-26-117604 ↗ |
| 8-K | 2026-02-12 | 2026-02-12 | 0001193125-26-047742 ↗ |
| 10-Q | 2026-02-12 | 2025-12-31 | 0001193125-26-047737 ↗ |
| 8-K | 2025-12-02 | 2025-12-01 | 0001193125-25-305475 ↗ |
| 8-K | 2025-11-14 | 2025-11-14 | 0001193125-25-283351 ↗ |
| 10-Q | 2025-11-14 | 2025-09-30 | 0001193125-25-283274 ↗ |
| 8-K | 2025-11-07 | 2025-11-05 | 0001193125-25-270490 ↗ |
| 8-K | 2025-11-03 | 2025-11-02 | 0001193125-25-261665 ↗ |
| 8-K | 2025-09-22 | 2025-09-22 | 0001193125-25-211462 ↗ |